Perth-based Avita Medical Ltd, formerly Clinical Cell Culture, has signed a distribution agreement with Greek company D.Analytica Ltd to supply its Funhaler spacer to the country's pharmacies and healthcare providers.
Perth-based Avita Medical Ltd, formerly Clinical Cell Culture, has signed a distribution agreement with Greek company D.Analytica Ltd to supply its Funhaler spacer to the country's pharmacies and healthcare providers.
D.Analytica has placed an initial order for the spacers valued at $44,000 with the official launch to take place in September, ahead of the winter season.
Additionally, Avita has also received regulatory approval in Mexico for the registration and importation of its ReCell product - a stand-alone, rapid cell harvesting device.
Below is the full announcement:
Funhaler® Paediatric Incentive Asthma Spacer. Avita Medical has signed a Distribution Agreement with Greek distributor D.Analytica Ltd to supply its innovative Funhaler® paediatric incentive spacer to Greek pharmacies and healthcare providers.
Based in Athens, D.Analytica is a specialist distributor of innovative medical products to pharmacies and hospitals throughout Greece. The company has longstanding relationships with influential paediatric specialists, leading hospitals, private clinics, and major chain pharmacies.
D.Analytica has placed an initial order of Funhaler® spacers valued at US$40,000. D.Analytica will officially launch the Funhaler® asthma spacer in September in advance of the Northern Hemisphere winter respiratory season and has commenced pre-marketing activities through attendance at key paediatric health care congresses.
Avita Medical's Chief Executive Officer Dr William Dolphin said: "We are very pleased to add D.Analytica to complement our European presence."
"Asthma remains a significant health care problem for Greek children and adolescents. In the last 10 years, Greece, with a population of approximately 11.2 million, has experienced a dramatic increase in diagnosed asthma and corresponding sales of bronchodilators. We are anticipating a high level of acceptance and uptake of the Funhaler product."
ReCell® Autologous Tissue Harvester.
Avita Medical is pleased to announce that the company has received regulatory approval from the Mexico Secretaria de Salud ("Salud") which approves the registration and importation of medical devices into Mexico for the sale and marketing of ReCell.
Avita Medical has worked closely with local distributor, PESSE (Productos, Equipos y Servicios de Salud Especializados S.A. de C.V.) in securing Mexican regulatory approval.
PESSE is focussed on the burns and plastic surgery markets in Mexico and is among the leading providers of specialty products for the hospitals, burns and plastic surgery clinics.
Dr Dolphin said, "The Mexican regulatory process is complex and time consuming and ReCell® approval by Salud is a significant milestone for Avita Medical."
"We will continue to focus our efforts on key markets with high potential for our products and in which regulatory approval is in place or in which the approval process is well advanced.
"We have been impressed with PESSE's efforts in obtaining approval and look forward to a productive working relationship," said Dr Dolphin.
